Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 18/20 | 1.00 |
| ▸ | ERCC5 | P28715 | 5/20 | 0.53 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.53 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959667 | 1.00 | FEN1 (1.00) | FEN1ERCC5ERCC1ERCC4CA12 | |
| SCHEMBL29960006 | 0.77 | FEN1 (0.62) | FEN1ERCC5ERCC1ERCC4CA12 | |
| SCHEMBL18670359 | 0.77 | FEN1 (1.00) | FEN1ERCC5CA12CA9 | |
| SCHEMBL18670345 | 0.76 | FEN1 (1.00) | FEN1ERCC5 | |
| SCHEMBL29959859 | 0.76 | FEN1 (1.00) | FEN1ERCC5 | |
| SCHEMBL18670454 | 0.75 | FEN1 (1.00) | FEN1ERCC5ERCC1ERCC4CA12 | |
| SCHEMBL29960340 | 0.75 | FEN1 (1.00) | FEN1ERCC5ERCC1ERCC4CA12 | |
| SCHEMBL12661603 | 0.70 | FEN1 (1.00) | FEN1ERCC5ERCC1ERCC4CA12 | |
| SCHEMBL18687484 | 0.69 | FEN1 (1.00) | FEN1ERCC5ERCC1ERCC4CA12 | |
| SCHEMBL1886475 | 0.68 | FEN1 (1.00) | FEN1ERCC5ERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253521-B2 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11253521-B2 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2022-02-22 | — | — | US | disclosed |
| EP-3353154-B1 | 3-HYDROXY-7-(SULFONYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND 3-HYDROXY-PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES AND RELATED COMPOUNDS AS FLAP-ENDONUCLEASE 1 (FEN-1) INHIBITORS FOR USE IN CANCER THERAPY | LUDWIG INST FOR CANCER RES LTD (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-20200237763-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2020-07-30 | — | — | US | disclosed |
| US-20200237763-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2020-07-30 | — | — | US | disclosed |
| EP-3353154-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | Ludwig Institute for Cancer Research Ltd (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017051251-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051251-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253521-B2 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | FEN1, ERCC4, XPA | FEN1 1/4885ERCC5 22/4885ERCC1 7/4885 |
| US-20200237763-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | FEN1, ERCC4, XPA | FEN1 1/4885ERCC5 22/4885ERCC1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.